Mark Penney
Impact in
- Genetics top 10%
- Inflammatory Bowel Disease
- Glioma Diagnosis and Treatment
- Molecular Biology top 10%
- Prion Diseases and Protein Misfolding
Papers in
- Genetics 2
- Glioma Diagnosis and Treatment 2
- Inflammatory Bowel Disease 2
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- David A. Hilton (4 shared papers)Linda McCardle (2 shared papers)Diane L. Ritchie (2 shared papers)James W. Ironside (2 shared papers)Azra C. Ghani (1 shared paper)René van der Merwe (3 shared papers)Paul Newbold (3 shared papers)Jörn Drappa (2 shared papers)
- Journals
- CPT Pharmacometrics & Systems Pharmacology (6 papers)mAbs (2 papers)Gastroenterology (2 papers)The Journal of Pathology (1 paper)Blood (1 paper)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Mark Penney
21 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 62
- Genetics 210
- Genetics 61
- Molecular Biology 374
- Cancer Research 33
- Cardiology and Cardiovascular Medicine 58
Countries citing papers authored by Mark Penney
This map shows the geographic impact of Mark Penney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Penney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Penney more than expected).
Fields of papers citing papers by Mark Penney
This network shows the impact of papers produced by Mark Penney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Penney. The network helps show where Mark Penney may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Penney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 333 | |
| 2 | 2017 | 236 | |
| 3 | 2023 | 88 | |
| 4 | 2017 | 82 | |
| 5 | 2002 | 79 | |
| 6 | 2015 | 71 | |
| 7 | 2018 | 69 | |
| 8 | 2019 | 68 | |
| 9 | 2004 | 58 | |
| 10 | 2019 | 49 | |
| 11 | 2004 | 33 | |
| 12 | 2020 | 26 | |
| 13 | 2002 | 23 | |
| 14 | 2015 | 19 | |
| 15 | 2014 | 18 | |
| 16 | 2021 | 18 | |
| 17 | 2013 | 9 | |
| 18 | 2016 | 8 | |
| 19 | 2023 | 6 | |
| 20 | 2024 | 2 |
About Mark Penney
Mark Penney is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine, Pharmacology and Genetics, having authored 23 papers that have together received 1.3k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (3 papers), Prion Diseases and Protein Misfolding (2 papers), Glioma Diagnosis and Treatment (2 papers), Antiplatelet Therapy and Cardiovascular Diseases (2 papers), Inflammatory Bowel Disease (2 papers), Cancer, Hypoxia, and Metabolism (1 paper), Pharmacogenetics and Drug Metabolism (1 paper) and Pancreatic function and diabetes (1 paper). The work is most often cited by research in Genetics (210 citations), Genetics (61 citations), Molecular Biology (374 citations), Cancer Research (33 citations) and Cardiology and Cardiovascular Medicine (58 citations). Mark Penney has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include David A. Hilton, Linda McCardle, Diane L. Ritchie, James W. Ironside, Azra C. Ghani, René van der Merwe, Paul Newbold, Jörn Drappa, Andrew Glenn Demaine and Erik P. Pulkstenis. Their work appears in journals such as CPT Pharmacometrics & Systems Pharmacology, mAbs, Gastroenterology, The Journal of Pathology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.